Population,Intervention,Comparison,Outcome,Measure,Effect,CI Lower,CI Upper,Significant,Number of participants,Number of studies,Certainty of the evidence (GRADE),Reasons for GRADE if not High,Risk of bias,Imprecision,Inconsistency,Indirectness,Publication bias
People on continuous oral anticoagulant treatment,Antifibrinolytic therapy (tranexamic acid (TXA) OR epsilon aminocaproic acid (EACA)),Placebo,"Postoperative bleedings requiring intervention (placebo control, 7 days follow-up)",RD,-0.25,-0.36,-0.14,TRUE,128,2,Moderate,The evidence is downgraded once to moderate due to relatively small sample sizes (imprecision),FALSE,TRUE,FALSE,FALSE,FALSE
People on continuous oral anticoagulant treatment,Antifibrinolytic therapy (tranexamic acid (TXA) OR epsilon aminocaproic acid (EACA)),Standard Care,"Postoperative bleedings requiring intervention (standard care control, 7 days follow-up)",RD,0.02,-0.07,0.11,FALSE,125,2,Moderate,The evidence is downgraded once to moderate due to relatively small sample sizes (imprecision),FALSE,TRUE,FALSE,FALSE,FALSE
People on continuous oral anticoagulant treatment,Antifibrinolytic therapy (tranexamic acid (TXA) OR epsilon aminocaproic acid (EACA)),Placebo,"Side effects or other adverse events requiring withdrawal (placebo control, 7 days follow-up)",RD,0,-0.04,0.04,FALSE,128,2,Moderate,The evidence is downgraded once to moderate due to relatively small sample sizes (imprecision),FALSE,TRUE,FALSE,FALSE,FALSE
